Literature DB >> 11083630

Characterization of spontaneous, In vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv.

G P Morlock1, B B Plikaytis, J T Crawford.   

Abstract

Resistance to rifampin in Mycobacterium tuberculosis results from mutations in the gene coding for the beta subunit of RNA polymerase (rpoB). At least 95% of rifampin-resistant isolates have mutations in rpoB, and the mutations are clustered in a small region. About 40 distinct point mutations and in-frame insertions and deletions in rpoB have been identified, but point mutations in two codons, those coding for Ser(531) and His(526), are seen in about 70% of rifampin-resistant clinical isolates, with Ser(531)-to-Leu (TCG-to-TGG) mutations being by far the most common. To explore this phenomenon, we isolated independent, spontaneous, rifampin-resistant mutant versions of well-characterized M. tuberculosis laboratory strain H37Rv by plating 100 separate cultures, derived from a single low-density inoculum, onto rifampin-containing medium. Rifampin-resistant mutants were obtained from 64 of these cultures. Although we anticipated that the various point mutations would occur with approximately equal frequencies, sequencing the rpoB gene from one colony per plate revealed that 39 (60.9%) were Ser(531) to Leu. We conclude that, for unknown reasons, the associated rpoB mutation occurs at a substantially higher rate than other rpoB mutations. This higher mutation rate may contribute to the high percentage of this mutation seen in clinical isolates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083630      PMCID: PMC90195          DOI: 10.1128/AAC.44.12.3298-3301.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Molecular analysis of rifampin and isoniazid resistance of Mycobacterium tuberculosis clinical isolates in Seville, Spain.

Authors:  N González; M J Torres; J Aznar; J C Palomares
Journal:  Tuber Lung Dis       Date:  1999

2.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.

Authors:  A Telenti; P Imboden; F Marchesi; D Lowrie; S Cole; M J Colston; L Matter; K Schopfer; T Bodmer
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

3.  Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas.

Authors:  V Kapur; L L Li; S Iordanescu; M R Hamrick; A Wanger; B N Kreiswirth; J M Musser
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

4.  Universal pattern of RpoB gene mutations among multidrug-resistant isolates of Mycobacterium tuberculosis complex from Africa.

Authors:  K Schilke; K Weyer; G Bretzel; B Amthor; J Brandt; V Sticht-Groh; P B Fourie; W H Haas
Journal:  Int J Tuberc Lung Dis       Date:  1999-07       Impact factor: 2.373

5.  A Ser315Thr substitution in KatG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St. Petersburg area in Russia.

Authors:  H J Marttila; H Soini; E Eerola; E Vyshnevskaya; B I Vyshnevskiy; T F Otten; A V Vasilyef; M K Viljanen
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

6.  Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Greece.

Authors:  P Matsiota-Bernard; G Vrioni; E Marinis
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

7.  The rpoB gene of Mycobacterium tuberculosis.

Authors:  L P Miller; J T Crawford; T M Shinnick
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  DNA repair in Mycobacterium tuberculosis. What have we learnt from the genome sequence?

Authors:  V Mizrahi; S J Andersen
Journal:  Mol Microbiol       Date:  1998-09       Impact factor: 3.501

9.  Characterization of rifampin-resistance in pathogenic mycobacteria.

Authors:  D L Williams; C Waguespack; K Eisenach; J T Crawford; F Portaels; M Salfinger; C M Nolan; C Abe; V Sticht-Groh; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study.

Authors:  B Heym; N Honoré; C Truffot-Pernot; A Banerjee; C Schurra; W R Jacobs; J D van Embden; J H Grosset; S T Cole
Journal:  Lancet       Date:  1994-07-30       Impact factor: 79.321

View more
  29 in total

Review 1.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  DNA alkylation damage as a sensor of nitrosative stress in Mycobacterium tuberculosis.

Authors:  Steven I Durbach; Burkhard Springer; Edith E Machowski; Robert J North; K G Papavinasasundaram; M Jo Colston; Erik C Böttger; Valerie Mizrahi
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

3.  Three nth homologs are all required for efficient repair of spontaneous DNA damage in Deinococcus radiodurans.

Authors:  Xiaoting Hua; Xin Xu; Mingfeng Li; Chao Wang; Bing Tian; Yuejin Hua
Journal:  Extremophiles       Date:  2012-04-21       Impact factor: 2.395

4.  The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis.

Authors:  Gwenan M Knight; Caroline Colijn; Sourya Shrestha; Mariam Fofana; Frank Cobelens; Richard G White; David W Dowdy; Ted Cohen
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

5.  A genotypic approach for detection, identification, and characterization of drug resistance in Mycobacterium ulcerans in clinical samples and isolates from Ghana.

Authors:  Marcus Beissner; Nana-Yaa Awua-Boateng; William Thompson; Willemien A Nienhuis; Erasmus Klutse; Pius Agbenorku; Joerg Nitschke; Karl-Heinz Herbinger; Vera Siegmund; Erna Fleischmann; Ohene Adjei; Bernhard Fleischer; Tjip S van der Werf; Thomas Loscher; Gisela Bretzel
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

6.  Evaluation of the TB-Biochip oligonucleotide microarray system for rapid detection of rifampin resistance in Mycobacterium tuberculosis.

Authors:  Janice C Caoili; Angelina Mayorova; David Sikes; Laura Hickman; Bonnie B Plikaytis; Thomas M Shinnick
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

7.  Resistance levels and rpoB gene mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants.

Authors:  Emma Huitric; Jim Werngren; Pontus Juréen; Sven Hoffner
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

8.  Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence.

Authors:  O J Strauss; R M Warren; A Jordaan; E M Streicher; M Hanekom; A A Falmer; H Albert; A Trollip; E Hoosain; P D van Helden; T C Victor
Journal:  J Clin Microbiol       Date:  2008-02-13       Impact factor: 5.948

9.  Identification of Nudix hydrolase family members with an antimutator role in Mycobacterium tuberculosis and Mycobacterium smegmatis.

Authors:  T Dos Vultos; J Blázquez; J Rauzier; I Matic; B Gicquel
Journal:  J Bacteriol       Date:  2006-04       Impact factor: 3.490

10.  Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations.

Authors:  J L Klein; T J Brown; G L French
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.